Efalizumab is a recombinant humanized anti-CD11a monoclonal antibody that blocks the activation, adhesion and trafficking of T cells and has been approved for the treatment of moderate-to-severe plaque psoriasis. To document management of the fluctuations in symptom control that patients with psoriasis sometimes experience during treatment, we performed a retrospective analysis of our experience using cyclosporine as an intercurrent treatment to control psoriasis-related adverse events (AEs) in 10 patients who had received continuous efalizumab therapy for 20–200 weeks prior to recurrence of symptoms. Combination therapy with cyclosporine and efalizumab was generally well tolerated and controlled the relapse effectively. There were no reports of severe AEs during combination treatment, and no clinically significant changes were noted in clinical and laboratory values. Although mild, localized psoriasis recurred in most of these patients after cyclosporine termination, no patient experienced rebound or psoriasis flare and all continued with long-term efalizumab treatment.

Keywords:
Efalizumab, Generalized inflammatory flare
1.
Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004;9:136–139.
2.
Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485–496.
3.
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280–284.
4.
Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y: The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383–392.
5.
Tristani-Firouzi P, Krueger GG: Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61(suppl):11–21.
6.
Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, Walicke P, Dummer W, Wang X, Garovoy MR, Pariser D; Efalizumab Study Group: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–2013.
7.
Kuypers TW, Roos D: Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: a review of functional and regulatory aspects. Res Immunol 1989;140:461–486.
8.
Dustin ML, Springer TA: Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988;107:321–331.
9.
Werther WA, Gonzalez TN, O’Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157:4986–4995.
10.
Jullien D, Prinz JC, Langley RG, Caro I, Dummer W, Joshi A, Dedrick R, Natta P: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004;208:297–306.
11.
Krueger GG: Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis. Expert Opin Biol Ther 2002;2:431–441.
12.
Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M: Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591–600.
13.
Barde C, Thielen AM, Saurat JH: Infliximab then efalizumab, the ‘hit and run’ approach does not work. Dermatology 2008;216:171–172.
14.
Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D: Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006;54(suppl 1):S171–S181.
15.
Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209–217.
16.
Cather JC, Menter A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003;3:361–370.
17.
Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB: Efalizumab: results of a three-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008;158:1107–1116.
18.
Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA; CLEAR Multinational Study Group: Clinical experience acquired with the efalizumab (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170–181.
19.
Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425–433.
20.
Costanzo A, Peris K, Talamonti M, Di Cesare A, Fargnoli MC, Botti E, Chimenti S: Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007;156(suppl 2):17–23.
21.
Leonardi CL: Efalizumab in the treatment of psoriasis. Dermatol Ther 2004;17:393–400.
22.
Scheinfeld N: Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006;5:197–209.
23.
Hamilton TK: Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005;24:19–27.
24.
Selenko-Gebauer N, Karlhofer F, Stingl G: Efalizumab in routine use: a clinical experience. Br J Dermatol 2007;156(suppl 2):1–6.
25.
Ulmer A, Woelbing F, Metzler G, Schanz S, Fierlbeck G, Roecken M: Severe exacerbation of chronic plaque psoriasis following initially effective therapy with efalizumab: clinical characterization and therapeutic management. Br J Dermatol 2008;158:867–869.
26.
Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM; Efalizumab Study Group: Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007;46:637–648.
27.
Gisondi P, Giglio MD, Girolomoni G: Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study. J Dermatol Treat 2006;17:172–175.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.